Co-Diagnostics (CODX) Competitors

Nephros (NASDAQ:NEPH) and Co-Diagnostics (NASDAQ:CODX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings, community ranking and media sentiment.

Does the media favor NEPH or CODX?

In the previous week, Co-Diagnostics had 2 more articles in the media than Nephros. MarketBeat recorded 4 mentions for Co-Diagnostics and 2 mentions for Nephros. Nephros' average media sentiment score of 0.43 beat Co-Diagnostics' score of 0.22 indicating that Nephros is being referred to more favorably in the media.

Company	Overall Sentiment
Nephros	Neutral
Co-Diagnostics	Neutral

Do insiders and institutionals hold more shares of NEPH or CODX?

41.1% of Nephros shares are owned by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are owned by institutional investors. 6.7% of Nephros shares are owned by company insiders. Comparatively, 8.4% of Co-Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Is NEPH or CODX more profitable?

Nephros has a net margin of -6.86% compared to Co-Diagnostics' net margin of -563.93%. Nephros' return on equity of -11.39% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nephros	-6.86%	-11.39%	-8.30%
Co-Diagnostics	-563.93%	-54.94%	-49.28%

Which has stronger valuation and earnings, NEPH or CODX?

Nephros has higher revenue and earnings than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nephros	$15.52M	2.60	-$1.58M	$0.07	54.29
Co-Diagnostics	$3.71M	2.67	-$35.33M	-$1.17	-0.25

Do analysts rate NEPH or CODX?

Nephros currently has a consensus target price of $5.00, indicating a potential upside of 31.58%. Co-Diagnostics has a consensus target price of $5.50, indicating a potential upside of 1,764.41%. Given Co-Diagnostics' higher possible upside, analysts clearly believe Co-Diagnostics is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nephros	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Co-Diagnostics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00

Which has more risk & volatility, NEPH or CODX?

Nephros has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, Co-Diagnostics has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500.

Does the MarketBeat Community prefer NEPH or CODX?

Co-Diagnostics received 262 more outperform votes than Nephros when rated by MarketBeat users. Likewise, 62.93% of users gave Co-Diagnostics an outperform vote while only 43.33% of users gave Nephros an outperform vote.

Company	Underperform	Outperform
Nephros	Outperform Votes 13 43.33%	Underperform Votes 17 56.67%
Co-Diagnostics	Outperform Votes 275 62.93%	Underperform Votes 162 37.07%

Summary

Nephros beats Co-Diagnostics on 9 of the 17 factors compared between the two stocks.